-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PLX-038 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PLX-038 in Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PLX-038 in Ovarian Cancer Drug Details: PLX-038 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PLX-038 in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PLX-038 in Peritoneal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PLX-038 in Peritoneal Cancer Drug Details: PLX-038 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TRX-920 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TRX-920 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TRX-920 in Solid Tumor Drug Details: TRX-920 is under development for...
-
Product Insights
Rectal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Rectal Cancer - Drugs In Development, 2023’, provides an overview of the Rectal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Sector Analysis
Neuromodulation Devices Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
Neuromodulation Devices Market Report Overview The neuromodulation devices market size was valued at $6.06 billion in 2023. Factors such as deep brain stimulation and spinal cord stimulation will drive the market growth at a CAGR of more than 6% from 2023 to 2033. Neuromodulation is one of the fastest-growing medical device markets. Within the last 10 years, the market has grown exponentially, with spinal cord stimulation being the largest market. Neuromodulation Devices Market Outlook 2023-2033 ($ Billion) Buy Full Report...
-
Product Insights
Spinal Fusion Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Spinal Fusion Pipeline Market Report Overview Spinal Fusion procedures are mainly performed on the cervical and thoracolumbar regions. Spinal fusion is a surgical procedure that involves joining two vertebrae in the spine to form a single solid bone, with the involvement of certain devices, to relieve pain. Conventional and Minimally Invasive Surgery (MIS) methods are used to perform Spinal Fusion. Conventional methods include all open surgical methods that are used for performing spinal procedures. The Spinal Fusion pipeline market research...
-
Product Insights
Alimit
Alimit is a Hydro project located in Cordillera Administrative Region, Philippines. The project is owned by Aboitiz Power Corp; SN Power AS and is developed by SN Aboitiz Power Group. The project is at the permitting stage. Empower your strategies with our Alimit report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PEN-866 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PEN-866 in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PEN-866 in Ovarian Cancer Drug Details: PEN-866 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PEN-866 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PEN-866 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PEN-866 in Colorectal Cancer Drug Details: PEN-866 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PEN-866 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PEN-866 in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PEN-866 in Gastric Cancer Drug Details: PEN-866 is under development for...